Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bergh

Showing results (201-210 of 233) with videos related to

Pageof 24
Sort By:
ESMO Open|May 29, 2026
Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trialP Filis, X Liu, A Matikas, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Benchmarking cancer outcomes in Europe: a scoping review of methodologies and case-mix adjustmentsJ Thurell, L Doppelbauer, E M Verheul, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2000
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast groupL Hakamies-Blomqvist, M Luoma, J Sjöström, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2007
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcomeJ Bergqvist, J F Ohd, J Smeds, et al.
Breast (Edinburgh, Scotland)|August 24, 2013
Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxelB K Linderholm, E Lidbrink, E Tallroth, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2003
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancerM-L Luoma, L Hakamies-Blomqvist, J Sjöström, et al.
Journal of Advanced Nursing|September 1, 2001
Timing of quality of life (QoL) assessments as a source of error in oncological trialsL Hakamies-Blomqvist, M L Luoma, J Sjöström, et al.
Angiogenesis|December 18, 2007
Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factorShaker A Mousa, Joel J Bergh, Emie Dier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2018
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patientsA Matikas, T Foukakis, V Moebus, et al.
Nature Medicine|May 13, 2003
Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreasJennifer A Doll, Veronica M Stellmach, Noël P Bouck, et al.
Pageof 24

Showing results (201-210 of 233) with videos related to

Sort By:
Pageof 24
ESMO Open|May 29, 2026
Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trialP Filis, X Liu, A Matikas, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Benchmarking cancer outcomes in Europe: a scoping review of methodologies and case-mix adjustmentsJ Thurell, L Doppelbauer, E M Verheul, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2000
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast groupL Hakamies-Blomqvist, M Luoma, J Sjöström, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2007
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcomeJ Bergqvist, J F Ohd, J Smeds, et al.
Breast (Edinburgh, Scotland)|August 24, 2013
Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxelB K Linderholm, E Lidbrink, E Tallroth, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2003
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancerM-L Luoma, L Hakamies-Blomqvist, J Sjöström, et al.
Journal of Advanced Nursing|September 1, 2001
Timing of quality of life (QoL) assessments as a source of error in oncological trialsL Hakamies-Blomqvist, M L Luoma, J Sjöström, et al.
Angiogenesis|December 18, 2007
Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factorShaker A Mousa, Joel J Bergh, Emie Dier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2018
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patientsA Matikas, T Foukakis, V Moebus, et al.
Nature Medicine|May 13, 2003
Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreasJennifer A Doll, Veronica M Stellmach, Noël P Bouck, et al.
Pageof 24